Pentamidine

• Description:

  Pentamidine (MP-601205) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine inhibits parasite Leishmania infantum with an IC50 of 2.5 μM. Pentamidine is a potent and selective protein tyrosine phosphatases (PTPases) and phosphatase of regenerating liver (PRL) inhibitor. Pentamidine has the potential for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment. Antitumor and antibacterial activities[1][2][3][4].

• Product Name Alternative:

  MP-601205

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Antibiotic; Bacterial; Fungal; Parasite; Phosphatase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/pentamidine.html

• Purity:

  97.19

• Solubility:

  DMSO : 3.3 mg/mL (ultrasonic; warming; adjust pH to 6 with 1 M HCl; heat to 60°C)

• Smiles:

  N=C (C1=CC=C (OCCCCCOC2=CC=C (C (N) =N) C=C2) C=C1) N

• Molecular Formula:

  C19H24N4O2

• Molecular Weight:

  340.42

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [2]Nguewa, P.A., et al., Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers, 2005. 2 (10) : p. 1387-400.|[3]Sands M, et al. Pentamidine: a review. Rev Infect Dis. 1985 Sep-Oct;7 (5) :625-34.|[4]David C. Bean, et al. Pentamidine: a drug to consider re-purposing in the targeted treatment of multi-drug resistant bacterial infections? J Lab Precis Med 2017;2:49.|[1]Pathak MK, et al. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002 Dec;1 (14) :1255-64.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  Leishmania; Trypanosoma

• Citation 01:

  Biochem Biophys Res Commun. 2019 Sep 17;517 (2) :221-226.|BMC Womens Health. 2022 Nov 24;22 (1) :470.|Drug Des Devel Ther. 2021 Jul 1;15:2857-2868.|Immunity. 2023 Feb 14;56 (2) :272-288.e7.|Int J Mol Sci. 2023 Sep 7;24 (18) :13812.|Microbiol Spectr. 2023 Jun 15;11 (3) :e0313822.|Molecules. 2020 Apr 23;25 (8) :1980.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.

• CAS Number:

  100-33-4